about
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.Tofacitinib for the treatment of psoriasis.Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.Brodalumab for the treatment of psoriasis.Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients.Tildrakizumab for treating psoriasis.The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis.Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis.HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis.Linear psoriasis following the typical distribution of the sciatic nerve.IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.New insight into the pathogenesis of nail psoriasis and overview of treatment strategies.What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice.Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients.Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.Pharmacogenetics of psoriasis:HLA-Cw6but notLCE3B/3Cdeletion norTNFAIP3polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumabEfficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessmA clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumabTreating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast TherapyA safety evaluation of guselkumab for the treatment of psoriasisSecukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observationPsoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA studyPsoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumabSpotlight on brodalumab in the treatment of plaque psoriasis: the evidence to dateClinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literatureReal life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkersUstekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experiencePharmacotherapeutic management of psoriasis in adolescents and childrenHigh-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumabIn which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasisSkin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligoSkin immunity and its dysregulation in psoriasisSuccessful treatment of psoriatic crumbly nails with ustekinumab
P50
Q36202783-A2384A05-939A-42C8-90F4-255D41DCA743Q36755241-B0A919D6-8B4D-49AE-8A45-5A73B2BAE014Q37251321-E0CB4E2F-19F1-4A38-BC9A-50AA8FD7DE7EQ38856883-38936E0C-0D34-4D29-A475-326A5BEA1865Q38957282-78031B59-9A5B-4852-820B-A49066855263Q38975719-66AAB63F-7D7C-4816-80B4-0DD1F88BDB03Q38983870-DB5FB8D2-1F5B-47A3-9CC8-43779D9174A2Q39167757-A6283BE5-7667-49B7-8E40-F2A96E7CD657Q39218034-38AEDA8C-2E79-48DF-BC19-54C45D32A2BAQ39244594-46457DB9-9A48-46D6-A167-761CA204BB4CQ39275772-C77CF0CA-63FE-4E4E-9D1E-C89387BD8DBDQ39869674-E9FC31EC-2685-4BDE-9C77-E26BE68D1E29Q39982486-FFC7AC12-9B2D-4DF8-9F1B-851BC670D4E1Q40201234-C6CC7934-5A07-480F-9724-08C24B81C6EBQ41633453-FEF16D59-5016-43F0-ACB3-70361B818A94Q43623630-1B8A3214-D280-47AC-BF78-C053A9B455D0Q47230622-97484243-3A62-4627-A882-C7F9279A4687Q47291490-597A5DF9-F2FF-4A58-8E26-A23D48D25ADEQ48092986-CDD8B412-989E-4B69-9FF2-60255F7A1928Q50545844-78D2516D-FAD7-4932-8E48-A99338187B46Q50927361-64A1056E-0A46-4CB4-A0D0-4D697E481F53Q51191920-699F655A-CEFC-4031-A97D-5EB8E3298672Q58434824-3F596A91-437E-445A-A8D8-94E7BBDF9CA6Q58823361-F424DC1D-1384-42CA-BB41-57778BE2C2FBQ59309366-77F00297-203A-4CBD-BB8F-84E2362B6F49Q59309372-88622767-D1ED-4429-BE98-245F6F07DD06Q59309377-DE632712-8DEC-4A35-AA99-A465FA92B91BQ59309381-0F3C3D29-F9CB-4C63-A4B6-FF3399CDBDD9Q59309384-554A27D9-1B25-4E3F-BFA5-D2DE9DCA55D8Q59309387-4CD42BF6-A770-4CEF-A5CB-3750381C52DCQ64073212-D317A39E-9DF0-464B-9096-FB6EFD282E0CQ89654840-061F1A0B-8966-4545-8DE9-F96CD5FA0772Q90840395-098F1096-88A1-4B39-AA8C-527849B1873AQ90878970-28C071F0-C4C2-4B82-80B9-A4A7163933D8Q91604789-4A59A2C4-FC34-4B4E-9BDD-E5474B0D0DCEQ91842193-060D4909-C51B-43C2-8912-05B2E8F933C8Q92271247-0DC3A4FD-397A-4000-B544-7BCEA40E5FA1Q92437228-1D2885F2-4094-41F5-AE43-780812BDA346Q92643484-5E174955-D0CB-438F-957E-9176BBB02443Q92992553-45FD29A2-50D0-43D6-AC98-7BE5A96CFF77
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
M Galluzzo
@ast
M Galluzzo
@en
M Galluzzo
@es
M Galluzzo
@nl
type
label
M Galluzzo
@ast
M Galluzzo
@en
M Galluzzo
@es
M Galluzzo
@nl
prefLabel
M Galluzzo
@ast
M Galluzzo
@en
M Galluzzo
@es
M Galluzzo
@nl
P106
P1153
55357225800
P31
P496
0000-0002-3424-5175